StockData
Inovio Pharmaceuticals, Inc. logo

Inovio Pharmaceuticals, Inc. (INO) stock

INONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$1.69+0.06 (+3.68%)

Close on Nov 18, 2026Market cap $174.74MP/E –Yield –

Inovio Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Inovio Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$79.26M. For fiscal 2025 it was -$86.82M. The highest annual figure on record is -$13.96M in fiscal 2009.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$86.82M–
FY2024Dec 31, 2024-$112.40M–
FY2023Dec 31, 2023-$143.94M–
FY2022Dec 31, 2022-$267.57M–
FY2021Dec 31, 2021-$301.22M–
FY2020Dec 31, 2020-$124.08M–
FY2019Dec 31, 2019-$111.11M–
FY2018Dec 31, 2018-$94.09M–
FY2017Dec 31, 2017-$83.64M–
FY2016Dec 31, 2016-$76.24M–
FY2015Dec 31, 2015-$34.28M–
FY2014Dec 31, 2014-$39.50M–
FY2013Dec 31, 2013-$19.54M–
FY2012Dec 31, 2012-$23.49M–
FY2011Dec 31, 2011-$21.64M–
FY2010Dec 31, 2010-$19.22M–
FY2009Dec 31, 2009-$13.96M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$18.62M–
Q1 FY2026Mar 31, 2026-$21.95M–
Q4 FY2025Dec 31, 2025-$17.48M–
Q3 FY2025Sep 30, 2025-$21.21M–
Q2 FY2025Jun 30, 2025-$23.08M–
Q1 FY2025Mar 31, 2025-$25.05M–
Q4 FY2024Dec 31, 2024-$20.37M–
Q3 FY2024Sep 30, 2024-$27.35M–
Q2 FY2024Jun 30, 2024-$33.20M–
Q1 FY2024Mar 31, 2024-$31.48M–
Q4 FY2023Dec 31, 2023-$27.39M–
Q3 FY2023Sep 30, 2023-$35.55M–
Q2 FY2023Jun 30, 2023-$37.04M–
Q1 FY2023Mar 31, 2023-$43.95M–
Q4 FY2022Dec 31, 2022-$55.95M–
Q3 FY2022Sep 30, 2022-$35.76M–
Q2 FY2022Jun 30, 2022-$104.14M–
Q1 FY2022Mar 31, 2022-$71.73M–
Q4 FY2021Dec 31, 2021-$105.51M–
Q3 FY2021Sep 30, 2021-$59.95M–
Q2 FY2021Jun 30, 2021-$83.20M–
Q1 FY2021Mar 31, 2021-$52.55M–
Q4 FY2020Dec 31, 2020-$29.34M–
Q3 FY2020Sep 30, 2020-$36.33M–
Q2 FY2020Jun 30, 2020-$33.18M–
Q1 FY2020Mar 31, 2020-$25.23M–
Q4 FY2019Dec 31, 2019-$30.42M–
Q3 FY2019Sep 30, 2019-$23.95M–
Q2 FY2019Jun 30, 2019-$28.20M–
Q1 FY2019Mar 31, 2019-$28.54M–
Q4 FY2018Dec 31, 2018-$29.50M–
Q3 FY2018Sep 30, 2018-$26.64M–
Q2 FY2018Jun 30, 2018-$5.20M–
Q1 FY2018Mar 31, 2018-$32.75M–
Q4 FY2017Dec 31, 2017-$22.89M–
Q3 FY2017Sep 30, 2017-$29.19M–
Q2 FY2017Jun 30, 2017-$9.64M–
Q1 FY2017Mar 31, 2017-$21.93M–
Q4 FY2016Dec 31, 2016-$22.36M–
Q3 FY2016Sep 30, 2016-$20.20M–

More Inovio Pharmaceuticals figures

See a number that looks wrong?